A phase II and pharmacodynamic study of sunitinib in relapsed/refractory oesophageal and gastro-oesophageal cancers

[1]  Naotoshi Sugimoto,et al.  Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. , 2014, The Lancet. Oncology.

[2]  Paul D. Selid,et al.  Intravitreal bevacizumab and aflibercept for the treatment of exudative age-related macular degeneration. , 2014, Ophthalmic surgery, lasers & imaging retina.

[3]  S. Qin.  Phase III study of apatinib in advanced gastric cancer: A randomized, double-blind, placebo-controlled trial. , 2014 .

[4]  David C. Smith,et al.  Double‐blind, randomized, phase 2 trial of maintenance sunitinib versus placebo after response to chemotherapy in patients with advanced urothelial carcinoma , 2014, Cancer.

[5]  S. Spechler,et al.  Autocrine VEGF signaling promotes proliferation of neoplastic Barrett's epithelial cells through a PLC-dependent pathway. , 2014, Gastroenterology.

[6]  C. Fuchs,et al.  Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial , 2014, The Lancet.

[7]  S. Al-Batran,et al.  FOLFIRI plus sunitinib versus FOLFIRI alone in advanced chemorefractory esophagogastric cancer patients: A randomized placebo-controlled multicentric AIO phase II trial. , 2013 .

[8]  M. Shah,et al.  Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a biomarker evaluation from the AVAGAST randomized phase III trial. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  N. Hanna,et al.  Sunitinib Plus Paclitaxel in Patients with Advanced Esophageal Cancer: A Phase II Study from the Hoosier Oncology Groupe , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[10]  C. Mathers,et al.  Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 , 2010, International journal of cancer.

[11]  F. Vita.  Use of serum VEGF (SVEGF) levels to predict outcome of esophageal cancer (EC) patients undergoing preoperative chemoradiation (CRT). , 2010 .

[12]  Ines Gockel,et al.  Analysis of anti‐proliferative and chemosensitizing effects of sunitinib on human esophagogastric cancer cells: Synergistic interaction with vandetanib via inhibition of multi‐receptor tyrosine kinase pathways , 2009, International journal of cancer.

[13]  J. Knox,et al.  Sunitinib in solid tumors , 2009, Expert opinion on investigational drugs.

[14]  M. Michaelson,et al.  Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  Xiangyu Yang,et al.  Improving the pharmacokinetic parameter measurement in dynamic contrast‐enhanced MRI by use of the arterial input function: Theory and clinical application , 2008, Magnetic resonance in medicine.

[16]  L. Schwartz,et al.  Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  H. Kaplan,et al.  Complement Activation via Alternative Pathway Is Critical in the Development of Laser-Induced Choroidal Neovascularization: Role of Factor B and Factor H1 , 2006, The Journal of Immunology.

[18]  D. Richel,et al.  Gefitinib phase II study in second-line treatment of advanced esophageal cancer , 2004 .

[19]  C. Shou,et al.  Expression of vascular endothelial growth factor and its receptors KDR and Flt-1 in gastric cancer cells. , 2002, World journal of gastroenterology.

[20]  C. Eng,et al.  Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers. , 2000, Journal of the National Cancer Institute.

[21]  M. van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.

[22]  Jacques Ferlay,et al.  GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC Cancer Base No. 11 [Internet] , 2013 .

[23]  E. Chiorean.  Bevacizumab in Combination With Chemotherapy As First-Line Therapy in Advanced Gastric Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study , 2012 .

[24]  S. Rani,et al.  Intravitreal Bevacizumab , 2011 .

[25]  M Van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. , 2000, Journal of the National Cancer Institute.